Litcius/Paper detail

A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer

Bradley J. Monk, Thomas J. Herzog, George Wang, Spyros Triantos, Scott Maul, Roland E. Knoblauch, Tracy McGowan, Waleed S.W. Shalaby, Robert L. Coleman

2020Gynecologic Oncology43 citationsDOI

Topics & Concepts

TrabectedinMedicineOvarian cancerOncologyOpen labelInternal medicineDoxorubicinAdverse effectPharmacologyChemotherapyCancerSurgerySoft tissueSoft tissue sarcomaOvarian cancer diagnosis and treatmentPARP inhibition in cancer therapyEndometrial and Cervical Cancer Treatments
A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer | Litcius